GLP-1 access prompts eating disorder concerns in Philadelphia
Eating disorder specialists in Philadelphia are warning that access to GLP-1 weight-loss medicines could expose vulnerable people to harm, according to reporting by WHYY. Their concerns come as the drugs’ growing visibility in advertising and everyday life creates new pressures for some people in recovery.
Samantha DeCaro, a psychologist specialising in eating disorder treatment at The Renfrew Center in Philadelphia, told the broadcaster that the combination of potential harm and ready access was concerning. The report also described companies selling the medicines with limited medical and mental health screening or follow-up care.
These are concerns about particular patients and the circumstances in which medicines are offered, rather than evidence that GLP-1 treatment causes eating disorders across the wider population. WHYY’s account draws on interviews; it does not provide a study population, a comparison group or an estimate of how frequently harm occurs.
GLP-1 medicines enter an already difficult body-image culture
GLP-1 medicines act on a hormone pathway involved in appetite and blood glucose regulation. Some are used to treat type 2 diabetes, while others are prescribed for weight management. Their medical uses are distinct from the cultural messages surrounding thinness and rapid changes in body size.
For Gabriela Ponce, a New York City resident interviewed by WHYY, those messages have a long history. Growing up in Latin America, she encountered strong expectations about women’s figures. Magazine imagery and the diet and fitness culture of the 1990s added further pressure.
Ponce developed an eating disorder as a teenager and experienced bulimia and anorexia into her mid-20s. She eventually received treatment from a team that included psychologists, nutritionists and medical professionals.
More than a decade into recovery, she has become a mother and an athlete. She described an approach to wellbeing centred on strength, stamina and happiness, alongside continuing attention to her emotional and mental health.
Ponce and DeCaro describe different aspects of the pressure
Ponce told WHYY that the shift became apparent to her a couple of years ago, when friends she had not considered overweight began taking GLP-1 medicines and losing weight quickly. “I found it really triggering,” she said.
Her account also points to the reach of celebrity advertising. She had admired Serena Williams both for her tennis achievements and for a physique different from prevailing ideals. Seeing Williams become the face of a telehealth company prescribing and advertising GLP-1 medicines formed part of the change Ponce described.
Ponce said her social media feed was now filled with advertisements from companies selling the drugs. That focus on commercial messaging also runs through our coverage of complaints about weight-loss drug advertising and a Noom campaign centred on GLP-1 weight regain.
DeCaro’s concern was the potential consequence for susceptible patients. “There are people who, unfortunately, if they do take these products, it might cause tremendous harm,” she told WHYY. The report did not quantify that risk or identify a rate of relapse among people taking the medicines.
GLP-1 screening and follow-up remain open questions
WHYY’s reporting leaves important questions about how providers identify an existing eating disorder, assess vulnerability and monitor patients after prescribing. It does not set out a common screening standard or compare the practices of individual companies.
Nor does the account establish whether any particular GLP-1 medicine, dose or duration of treatment carries a different risk for people in recovery. The evidence presented supports attention to their experiences and to DeCaro’s warning, but cannot determine how broadly those experiences apply.
